Percent Positive by Reason for Testing
14.0% 12.0% 10.0% 8.0% 6.0% 4.0% 2.0% 0.0%
11.9% 6.3% 3.4% 5.6% 3.8% 5.7% 11.1% 5.3%
expansion of compounds, this law was writen to include the chemicals by their pharmaco- logical action rather than by named com- pounds as chemists world-wide are continu- ing to synthesize new synthetic cannabinoid compounds for distribution. Te use of synthetic cannabinoids domi-
nates the synthetic market sales, but syn- thetic stimulants are also widely produced and sold in a similar manner with signifi- cant health risk and addiction. Te Syn- thetic Drug Abuse Prevention Act of 2012 also addresses the synthetic stimulants in a similar manner. State laws regarding these compounds are highly variable and must be considered as new workplace policies are developed to include these compounds. ❚
Endnotes
1.
http://www.samhsa.gov/data/2k12/DAWN105/SR105- synthetic-marijuana.pdf
2.
http://www.govtrack.us/congress/bills/112/s3187/text
is multiple times the marijuana rate for DOT samples. Te high percentage use of synthet- ics in the Random and Pre-Employment samples further supports the widespread dis- tribution of these products and the publicity these products have received in the television news and print.
Current Legal Status Te results obtained by CRL over the last
12 months support the testing for synthetic cannabinoids in a workplace population. Te signing of the Synthetic Drug Abuse Prevention Act of 2012 by President Obama in July 2012 (Reference 2) has decreased the availability of these products by placing them into Federal Schedule I status and has driven these products underground. However, their availability is still prevalent. Due to the rapid
22 datia focus
David Kuntz, PhD, is the Executive Director for Analytical Toxicology at Clinical Reference Laboratory in Lenexa, Kansas. Dr. Kuntz is Co-Responsible Person for the SAMHSA lab- oratory and the College of American Patholo- gists (CAP) forensic drug testing Scientific Director. He holds a laboratory director license in a number of states and is an inspector for SAMHSA and CAP forensic programs.
He is a Board Certified Toxicologist and is a national expert in urine adulteration and drug detection in urine, oral fluid, and sweat using GC/MS and LC/MS/MS. Dr. Kuntz has worked in workplace drug testing for the past 24 years and has testified extensively regarding drug use, interpretation, and adulteration of urine, oral fluid and sweat samples.
winter 2013
Follow-up Not specified Other
Post Accident Pre-employment
Random
Reasonable cause Return to duty
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50